Palleon Pharmaceuticals

31 articles about Palleon Pharmaceuticals

• Palleon Pharmaceuticals Recognized as a Fierce Biotech “Fierce 15” Company for 2023

  8/28/2023

  Palleon Pharmaceuticals, a clinical-stage company pioneering glyco-immunology drug development to treat cancer and inflammatory diseases, announced that Fierce Biotech has recognized the company as one of its “Fierce 15” for 2023.

• Palleon Pharmaceuticals Announces First Patient Dosed with E-602 in Combination with Cemiplimab in GLIMMER-01 Phase 1/2 Clinical Trial

  6/22/2023

  Palleon Pharmaceuticals today announced that the first patient has been dosed in the combination therapy cohort of the Phase 1/2 clinical trial for E-602, its lead candidate from the EAGLE (Enzyme Antibody Glyco-Ligand Editing) oncology platform.

• Palleon Pharmaceuticals Presents Initial Phase 1 Results from the GLIMMER-01 Clinical Trial for E-602, the First Ever Glyco-Immune Checkpoint Inhibitor

  4/18/2023

  Palleon Pharmaceuticals, a clinical-stage company pioneering glyco-immunology drug development to treat cancer and inflammatory diseases, today announced the initial Phase 1 results from the GLIMMER-01 trial of its lead EAGLE oncology platform program, E-602, at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, Florida.

• Palleon Pharmaceuticals to Present at the Guggenheim Healthcare Talks Oncology Day

  2/7/2023

  Palleon Pharmaceuticals today announced that the company will present at the Guggenheim Healthcare Talks Oncology Day on Thursday, February 9, 2023.

• Palleon Announces Issuance of a U.S. Patent for Use of Antibody Sialidase Conjugates

  10/13/2022

  Palleon Pharmaceuticals today announced that the U.S. Patent and Trademark Office has issued Patent No.11,459,398 titled, “Conjugates for Targeted Cell Surface Editing.”

• Palleon Pharmaceuticals to Present at the Oppenheimer Healthcare Private Company Showcase

  10/12/2022

  Palleon Pharmaceuticals today announced that the company will present at the Oppenheimer Healthcare Private Company Showcase: The Next Wave on Tuesday, October 18, 2022.

• Palleon to Present on Phase 1/2 E-602 Bi-Sialidase Trial Design at Society for Immunotherapy of Cancer (SITC) Annual Meeting

  10/11/2022

  Palleon Pharmaceuticals, a clinical-stage company pioneering glyco-immunology drug development to treat cancer and inflammatory diseases, today announced that it will present on GLIMMER-01, the ongoing Phase 1/2 Trial of its lead program E-602 Bi-Sialidase at the Society for Immunotherapy of Cancer’s 37th Annual Meeting taking place in Boston from November 8-12, 2022.

• Palleon Co-Founder Dr. Carolyn Bertozzi Awarded Nobel Prize in Chemistry for Pioneering Methods of Studying Glycobiology

  10/5/2022

  Palleon Pharmaceuticals announced that the company’s scientific co-founder Carolyn Bertozzi, Ph.D., has been awarded the 2022 Nobel Prize in Chemistry.

• Palleon Pharmaceuticals and Henlius Enter into Strategic Collaboration to Develop Bifunctional Sialidase Therapies

  6/28/2022

  Palleon and Henlius to co-develop Bifunctional HER2-Sialidase and a second bifunctional sialidase to be jointly designed.

• Palleon Presents Preclinical Data on Lead Program E-602 and Novel Bifunctional PD-L1-Targeted Sialidase

  4/8/2022

  Palleon Pharmaceuticals, a company pioneering the field of glyco-immunology to treat cancer and inflammatory diseases, today presented new preclinical data on the company’s lead oncology program, E-602, as well as data supporting Palleon’s novel bifunctional PD-L1-Targeted Sialidase, in two poster presentations at the American Association for Cancer Research Annual Meeting in New Orleans, La.

• Palleon Pharmaceuticals to Present Preclinical Data on Lead Program E-602 and Novel Bifunctional PD-L1-Targeted Sialidase at AACR Annual Meeting

  3/9/2022

  Palleon Pharmaceuticals today announced two poster presentations at the American Association for Cancer Research Annual Meeting in New Orleans, La., from April 8-13, 2022.

• Palleon Pharmaceuticals Announces First Patient Dosed in Phase 1/2 Study of Lead Glyco-Immunology Drug Candidate for Oncology

  3/8/2022

  Palleon Pharmaceuticals, a company pioneering the field of glyco-immunology to treat cancer and inflammatory diseases, today announced dosing of the first patient in the company’s Phase 1/2 study of E-602 in patients with advanced cancers.

• Palleon Pharmaceuticals Announces IND Clearance for First-in-Class Cancer Immunotherapy Leveraging Glyco-Immunology

  1/20/2022

  Palleon Pharmaceuticals today announced that the U.S. Food and Drug Administration has cleared the company’s investigational new drug (IND) application for its lead candidate E-602.

• Palleon Pharmaceuticals Appoints Denis Patrick to Its Board of Directors

  12/16/2021

  Palleon Pharmaceuticals today announced the appointment of Denis Patrick, Ph.D., to its Board of Directors.

• Palleon Presents Data on Sialoglycan Degradation Platform That Enhances Anti-Tumor T-Cell Immunity

  11/9/2021

  Palleon Presents Data on Sialoglycan Degradation Platform That Enhances Anti-Tumor T-Cell Immunity

• Palleon Pharmaceuticals Appoints David Johnson to Its Board of Directors

  11/2/2021

  Palleon Pharmaceuticals today announced the appointment of David Johnson as an independent director to its Board of Directors.

• Palleon to Present Preclinical Data on Lead Immuno-Oncology Program, E-602, at SITC Annual Meeting

  10/25/2021

  Palleon Pharmaceuticals today announced it will present new preclinical data on the company’s lead immuno-oncology program, E-602, at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Washington, D.C., from November 10-14, 2021.

• Palleon Pharmaceuticals Appoints David Feltquate as Chief Medical Officer

  6/9/2021

  Palleon Pharmaceuticals, a company pioneering the field of glyco-immunology to treat cancer and inflammatory diseases, announced the appointment of David Feltquate, M.D., Ph.D., as Chief Medical Officer.

• Palleon Pharmaceuticals Presents Data Suggesting Role of Hypersialylation in Metastatic Melanoma Patients’ Resistance to PD1 Inhibitors

  4/9/2021

  Palleon Pharmaceuticals, a company pioneering the field of glycan-mediated immune regulation to treat cancer and inflammatory diseases, announced the presentation of data supporting the role of hypersialylation in the immune escape of metastatic melanoma at the AACR Annual Meeting held virtually April 10-15, 2021.

• Palleon Pharmaceuticals Appoints Nikola Trbovic to Its Board of Directors

  2/8/2021

  Palleon Pharmaceuticals, a company pioneering the field of glycan-mediated immune regulation to treat cancer and inflammatory diseases, today announced the appointment of Nikola Trbovic, Ph.D., Executive Director and Partner at Pfizer Ventures, as a member of its Board of Directors.